Before You Sell Nektar Therapeutics (NASDAQ: NKTR) Shares, Here’sWhat You Need To Know.

Nektar Therapeutics (NASDAQ:NKTR) shares, rose in value on Thursday, April 04, with the stock price up by 9.13% to the previous day’s close as strong demand from buyers drove the stock to $1.13.

Actively observing the price movement in the recent trading, the stock is buoying the session at $1.04. The value of beta (5-year monthly) is 0.91. Referring to stock’s 52-week performance, its high was $1.13, and the low was $0.41. On the whole, NKTR has fluctuated by 28.38% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

With the market capitalization of Nektar Therapeutics currently standing at about $208.41 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.19, which is expected to increase to -$0.15 for fiscal year -$0.88 and then to about -$0.71 by fiscal year 2025. Data indicates that the EPS growth is expected to be 39.30% in 2025, while the next year’s EPS growth is forecast to be 19.30%.

Analysts have estimated the company’s revenue for the quarter at $15.34 million, with a low estimate of $5.4 million and a high estimate of $20.62 million. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $67.51 million, representing a decrease of -25.10% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that NKTR’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of NKTR currently trading nearly 26.13% and 50.00% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 74.89, while the 7-day volatility ratio is showing 11.37% which for the 30-day chart, stands at 8.52%. Furthermore, Nektar Therapeutics (NKTR)’s beta value is 0.89, and its average true range (ATR) is 0.08.

A comparison of Nektar Therapeutics (NKTR) with its peers suggests the former has fared considerably weaker in the market. NKTR showed an intraday change of 9.13% in today’s session so far, and over the past year, it grew by 54.76%%.

Data on historical trading for Nektar Therapeutics (NASDAQ:NKTR) indicates that the trading volumes over the past 10 days have averaged 1.63 million and over the past 3 months, they’ve averaged 1.69 million. According to company’s latest data on outstanding shares, there are 191.38 million shares outstanding.

Nearly 2.98% of Nektar Therapeutics’s shares belong to company insiders and institutional investors own 65.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.51 million shares as on Mar 15, 2024, resulting in a short ratio of 0.93. According to the data, the short interest in Nektar Therapeutics (NKTR) stood at 1.37% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 2.45 million. The stock has risen by 100.88% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NKTR stock heading into the next quarter.